Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study-Reference-Cited by-同舟云学术

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

Published:2023-01 Issue: Volume:179 Page:15-24
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Imaji Mihoko,Fujimoto Daichi^ORCID,Sato Yuki,Sakata Yoshihiko,Oya Yuko^ORCID,Tamiya Motohiro,Suzuki Hidekazu,Ikeda Hideki,Kijima Takashi,Matsumoto Hirotaka^ORCID,Kanazu Masaki^ORCID,Hino Aoi,Inaba Megumi,Tsukita Yoko,Arai Daisuke^ORCID,Maruyama Hirotaka,Hara Satoshi,Tsumura Shinsuke^ORCID,Kobe Hiroshi,Sumikawa Hiromitsu,Sakata Shinya,Yamamoto Nobuyuki^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

3. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

4. Therapy for Stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J Clin Oncol,2020

5. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC;Suh;Lung Cancer,2018

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series;OncoTargets and Therapy;2024-08

2. EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis;Journal of Personalized Medicine;2024-07-15

3. Two Cases of EGFR-mutated Non-small-cell Lung Cancer Treated with Erlotinib+Ramucirumab After Osimertinib-induced Lung Injury;Haigan;2024-06-20

4. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101);Targeted Oncology;2024-04-13

5. Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease;JTO Clinical and Research Reports;2024-04